SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. – BOLT

NEW YORK, June 15, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Bolt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On May 14, 2024, Bolt announced in a press release that the Company would “cease further development of trastuzumab imbotolimod (BDC-1001)”, Bolt’s lead asset, “and reduce workforce by approximately 50%”. Following Bolt’s announcement, multiple analysts downgraded the Company’s stock. 

On this news, Bolt’s stock price fell $00.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bolt-biotherapeutics-inc—bolt-302172551.html

SOURCE Pomerantz LLP